Brief: Matinas Biopharma Reports Q3 2022 Financial Results
02/11/2022 20:21
Nov 2 (Reuters) - Matinas Biopharma Holdings Inc
MTNB.A :
* MATINAS BIOPHARMA REPORTS THIRD QUARTER 2022 FINANCIAL
RESULTS
AND HIGHLIGHTS RECENT PROGRESS
* MATINAS BIOPHARMA HOLDINGS- $33.1 MILLION IN CASH, CASH
EQUIVALENTS, AND MARKETABLE SECURITIES AT SEP 30, 2022,
SUFFICIENT TO FUND PLANNED OPERATIONS THROUGH 2023
* QTRLY NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS WAS
$5.5
MILLION, OR A NET LOSS OF $0.03 PER SHARE
* Q3 EARNINGS PER SHARE VIEW $-0.03 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNXbc0rSw
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing